Corcept Therapeutics INC Form 4 insider transactions

Corcept Therapeutics' President of Endocrinology, Sean Maduck, has filed a Form 4 detailing a series of share transfers to a family trust and the exercise of stock options, reflecting changes in beneficial ownership.

Gary Robb, Chief Business Officer of Corcept Therapeutics, reports the disposition and acquisition of company stock via sales and gifts.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold shares on May 16, 2025, according to a recent SEC filing.

David Mahoney, a director at Corcept Therapeutics, exercised stock options and sold shares on May 16, 2025, according to a Form 4 filing with the SEC.

Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold shares on May 12, 2025, according to a Form 4 filing with the SEC.

William Guyer, Chief Development Officer of Corcept Therapeutics, executed a stock option exercise and sale on May 6, 2025, according to a Form 4 filing.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics common stock on May 1st and 2nd, 2025, according to a Form 4 filing with the SEC.

Corcept Therapeutics CEO Joseph K. Belanoff executed sales of common stock on May 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on May 1, 2025, according to a Form 4 filing.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports changes in beneficial ownership of company stock, including shares held directly and indirectly through custodial accounts.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics (CORT) common stock on March 31, 2025, and April 1, 2025, according to a Form 4 filing with the SEC.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on March 31 and April 1, 2025, according to a Form 4 filing.

William Guyer, Chief Development Officer of Corcept Therapeutics, reports the acquisition and disposal of common stock and stock options on April 1, 2025, according to a Form 4 filing.

Corcept Therapeutics CEO Joseph K. Belanoff sold shares of common stock on March 31, 2025, and April 1, 2025, under a pre-arranged 10b5-1 trading plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on March 24, 2025, according to a recent SEC filing.

Corcept Therapeutics CEO Joseph Belanoff sold 1,974 shares of common stock at an average price of $60.8329 per share on March 24, 2025, under a pre-arranged 10b5-1 trading plan.

Sean Maduck, President of Corcept Endocrinology, reports the sale of 1,697 shares of Corcept Therapeutics stock at $60.58 per share, alongside the exercise of stock options.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports the transfer of common stock to custodial accounts for a child and discloses holdings including unvested restricted stock awards.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports changes in beneficial ownership of company stock due to gift transactions.

Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold shares on March 10, 2025, according to a Form 4 filing with the SEC.

Sean Maduck, President of Corcept Endocrinology, reports stock transactions including option exercises, stock sales, and tax withholding related to restricted stock units.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports stock transactions including acquisitions, disposals, and option exercises.

William Guyer, Chief Development Officer of Corcept Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

CEO Joseph Belanoff reports selling shares and receiving stock options in Corcept Therapeutics.

Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics, reports the acquisition of stock options in a recent SEC filing.

Atabak Mokari, CFO of Corcept Therapeutics, reports acquisition and disposal of company stock, including shares withheld for tax obligations and shares acquired through a purchase plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports stock acquisitions, disposals, and option grants.

Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics, exercised stock options and disposed of shares to cover the exercise price and tax obligations.

Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold the acquired shares under a pre-arranged 10b5-1 trading plan.